ClinicalTrials.gg
Not yet recruitingNCT04052191MCRcI®Updated Oct 3, 2024

MCRcI® Stem Cell Treatment for Diffuse Coronary Artery Disease

A Phase 1 interventional study of MCRcI® stem cells in Coronary Artery Disease, sponsored by Honya Medical Inc. Not yet recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Honya Medical Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies in Coronary Artery Disease with a site in Taiwan — 12 open to participants now, 16 under way, 2 of them phase 3. Coronary Artery Disease · Taiwan.

Planned enrollment
44th of 51
40 · median 172
Started
2025
with 2 others
Phase 1
Only one
of the 68
Primary completion
2026-01
later than 2 of 15 live
Registered
43rd of 68
by date

Among the 68 studies in Coronary Artery Disease with a site in Taiwan, this one is the 44th largest by planned enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 1, reaches primary completion later than 2 of the 15 other live ones, and was the 43rd registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

12 of the 68 studies in Coronary Artery Disease with a site in Taiwan are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Coronary Artery Disease with a site in Taiwan, or all of them as a file.
02

Study summary

Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with Diffuse Coronary Artery Disease.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Diffuse Coronary Artery Disease
  • Age 20\~80
  • Participants have received proper medication
  • Canadian Cardiovascular Society class II- IV Angina.

Exclusion criteria

Exclusion Criteria:

  • Age \<20 or >80
  • Pregnant or breast feeding
  • Positive adventitious infection (such as , hepatitis )
  • History of Myocardial Infarction within past 3 months
  • Severe aortic or mitral valve narrowing
  • Short of breath unable to receive PCI examination or treatment
  • Malignant tumor
  • Hematopoietic dysplasia
  • Severe organ disease with less than 1 year of
  • Chronic kidney disease with CCr\<20ml/min
  • Kiney disease on renal dialysis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Low Dose

    Low Dose of MCRcI® stem cells.

    Biological: MCRcI® stem cells

  • Experimental
    Intermediate Dose

    Intermediate Dose of MCRcI® stem cells.

    Biological: MCRcI® stem cells

  • Experimental
    High Dose

    High Dose of MCRcI® stem cells.

    Biological: MCRcI® stem cells

Interventions

  • Intra-Coronary Administration of MCRcI® stem cells

    Also known as: stem cells

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events

    Number of adverse events

    Time frame: 6 months

Secondary outcomes

  1. Left ventricle stroke volume

    Echocardiogram assessment on left ventricle stroke volume (volume of blood pumped from the left ventricle per beat (ml).

    Time frame: 12 months

  2. End diastolic volume

    Echocardiogram assessment on volume of blood in the left ventricle at the end of diastolic filling (ml)

    Time frame: 12 months

  3. Left ventricular ejection fraction (LVEF)

    Calculated by dividing the volume of blood pumped from the left ventricle per beat (stroke volume) by the volume of blood collected in the left ventricle at the end of diastolic filling (end-diastolic volume).

    Time frame: 12 months

  4. Severity of angina symptom using Canadian Cardiovascular Society grading.

    Canadian Cardiovascular Society grading of angina pectoris is a classification system used to grade the severity of exertional angina. Scale ranges 0 \~ IV (most sever), with 0 Asymptomatic Angina, I Angina only with strenuous exertion, II Angina with moderate exertion, III Angina with mild exertion and IV Angina at rest.

    Time frame: 12 months

07

Study locations

1 site
  • HONYA Medical Inc
    Tainan, 74147, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Jan 2026, 1 month later.

Of 34 phase 1 interventional studies under Coronary Artery Disease, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2019
First posted
Aug 9, 2019
StartEst.
Dec 1, 2025
Primary completionEst.
Jan 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04052191
Lead sponsor
Honya Medical Inc
Responsible party
Sponsor
First posted
Aug 9, 2019
Start date
Dec 1, 2025 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 3, 2024

Study contacts

Jackson TK Liu, MD
Contact
honyamedical@gmail.com
+886921167980
Fang Y Lee, MD
principal investigator · Chang Gung Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion